Uso de Hidroxiureia em pacientes com anemia falciforme acompanhados no hospital universitário de Sergipe

• Autor(a) principal: Silva, Matheus Almeida Cardoso da
• Data de Publicação: 2019
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: https://ri.ufs.br/jspui/handle/riufs/15357
• topic: Anemia falciforme; Hidroxiuréia; Evolução clínica; Sickle cell anemia; Hydroxyurea; Clinical evolution; CIENCIAS DA SAUDE::MEDICINA

Introduction: - Sickle cell anemia (SCA) is a hereditary globulopathy that results in the creation of hemoglobin S, responsible for vaso-occlusion of blood vessels and inflammatory processes that cause injury to various organs and systems. Hydroxyurea (HU) is the main treatment for SCA because it increases the formation of HbF and is responsible for preventing clinical complications, improving quality of life and increasing patient survival. This study aims to demonstrate the relation between the use of HU in sickle cell pacients and several epidemiological, clinical and laboratory elements besides identifying pacients with medical indication of use but not in treatment yet. Methods: - It is a historical cohort study, with some variables evaluated transversally. The patients' charts were reviewed to obtain data on neonatal screening, age, sex, use of hydroxyurea, alloimmunization, laboratory variables, clinical complications and number of hospitalizations per year. The numerical variables will be expressed through central tendency measures: mean or median along with minimum and maximum values, comparisons between groups will be made by means of a means test (independent or paired "t" test, as appropriate). The level of statistical significance will be p <0.05. Results: - Of the 272 patients with sickle cell anemia, about 98 (or 36%) are treated with Hydroxyurea. They are associated with a higher mean age, less chance of having neonatal screening, more likely to have blood transfusion, and alloimmunization. There was also a direct relationship between the use of the drug and a higher probability of cholecystectomy, ACS, CVA, nephropathy, osteonecrosis and higher number of hospital admissions. In addition to the association with the increase of MCV and ferritin besides the decrease of WBC. Conclusion - The use of hydroxyurea was directly related to mean age, neonatal screening, alloimmunization, blood transfusion, cholecystectomy, ACS, CVA, number of hospital admissions, osteonecrosis, nephropathy, MCV, ferritin, WBC. It should be noted that, probably the use of HU started as a consequence of the clinical complications found because they are medical indications of treatment. Also it was identified that there are pacients with clinical indications of HU use but didn’t started the treatment yet.